Lanifibranor
- Generic Name
- Lanifibranor
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H15ClN2O4S2
- CAS Number
- 927961-18-0
- Unique Ingredient Identifier
- 28Q8AG0PYL
- Background
Lanifibranor is under investigation in clinical trial NCT03008070 (Phase 2b Study in NASH to Assess IVA337).
- Associated Conditions
- -
- Associated Therapies
- -
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
Inventiva secures €94.1M of up to €348M equity financing to advance lanifibranor in MASH Phase 3 NATiV3 trial, with over 1,100 patients enrolled. The company also appoints Mark Pruzanski, MD, as Chairman and Srinivas Akkaraju, MD, PhD, as director, pending shareholder approval.
Lanifibranor may promote liver gains seen in Phase 3 MASH trial
Improved liver health biomarkers and reduced scarring observed in MASH patients in lanifibranor Phase 3 trial, similar to Phase 2b NATIVE trial results. NATiV3 trial, enrolling 837 patients, aims to assess MASH resolution and fibrosis reduction at week 72, with interim data showing improved liver function and reduced fibrosis.
Related Clinical Trials:
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
Inventiva reports progress in NATiV3 trial with 85% patient enrollment, consistent baseline characteristics, and positive biomarker evolution. The company anticipates last patient randomization in H1 2025 and topline results in H2 2026. Financial update shows cash and cash equivalents at €10.1 million as of June 30, 2024, with a cash runway extended until mid-October 2024 following a €20.1 million royalty deal. Inventiva is actively seeking additional financing and discussing strategic options.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath